ArticleFrontiers in endocrinology2025
Risk factors and survival analysis of patients with distant metastatic follicular thyroid cancer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to identify clinicopathological risk factors associated with distant metastasis in follicular thyroid cancer (FTC) and to evaluate prognostic factors influencing survival in distant metastatic FTC patients, thereby providing evidence for risk stratification and personalized treatment strategies. Methods: In this retrospective study, we enrolled FTC patients who underwent total thyroidectomy, subtotal thyroidectomy, or thyroid lobectomy at the Affiliated Hospital of Qingdao University from January 2014 to December 2021. Eligible patients were divided into 2 groups: the distant metastasis group (DM group) and the group with no evidence of distant metastasis during the study period (NDM group). The DM group was further divided into the survival group and the mortality group at the last follow-up. Results: In total, 111 patients who underwent thyroid surgery were included. 30 patients (27.03%) had distant metastasis (DM group), and 81 patients (72.97%) had no distant metastasis (NDM group). Multivariate logistic regression analysis indicated that the FTC subtype (odds ratio [OR]: 141.244; 95% confidence interval [CI]: 7.128-2798.802; P = 0.001), the number of lymph node metastases LNMs (OR: 0.028; 95% CI: 0.001-0.563; P = 0.020), T stage (OR: 0.048; 95% CI: 0.003-0.766; P = 0.032) and the type of initial surgery (OR: 175.685; 95% CI: 6.452-4783.472; P = 0.002) were independent risk factors predicting DM. Overall, the 3-year cumulative survival rates of DM patients was 83.0%. Kaplan-Meier survival analysis revealed significant differences in the 3-year survival time according to T stage (P = 0.019). Conclusion: Widely invasive FTC, lymph node metastasis, T3/T4 stage, and initial total thyroidectomy are independent predictors of distant metastasis in FTC patients. For FTC patients with DM, high T stage may be related to a greater likelihood of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.